Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) EBT Margin: 2020-2025

Historic EBT Margin for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Sep 2025 value amounting to 28.18%.

  • Harmony Biosciences Holdings' EBT Margin fell 523.00% to 28.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.90%, marking a year-over-year increase of 219.00%. This contributed to the annual value of 26.84% for FY2024, which is 296.00% down from last year.
  • According to the latest figures from Q3 2025, Harmony Biosciences Holdings' EBT Margin is 28.18%, which was up 13.84% from 24.76% recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' EBT Margin peaked at 34.37% during Q4 2022, and registered a low of -13.03% during Q3 2021.
  • Its 3-year average for EBT Margin is 28.34%, with a median of 30.95% in 2025.
  • In the last 5 years, Harmony Biosciences Holdings' EBT Margin skyrocketed by 20,703bps in 2021 and then slumped by 2,030bps in 2024.
  • Quarterly analysis of 5 years shows Harmony Biosciences Holdings' EBT Margin stood at 26.83% in 2021, then spiked by 754bps to 34.37% in 2022, then crashed by 1,081bps to 23.57% in 2023, then skyrocketed by 433bps to 27.90% in 2024, then tumbled by 523bps to 28.18% in 2025.
  • Its EBT Margin stands at 28.18% for Q3 2025, versus 24.76% for Q2 2025 and 30.95% for Q1 2025.